Abbott Laboratories (ABT)
98.63
+9.36 (10.48%)
NYSE· Last Trade: Jul 16th, 2:06 PM EDT
Detailed Quote
| Previous Close | 89.27 |
|---|---|
| Open | 95.29 |
| Bid | 98.61 |
| Ask | 98.64 |
| Day's Range | 94.99 - 101.87 |
| 52 Week Range | 81.97 - 137.49 |
| Volume | 19,787,155 |
| Market Cap | 172.69B |
| PE Ratio (TTM) | 26.44 |
| EPS (TTM) | 3.7 |
| Dividend & Yield | 2.520 (2.56%) |
| 1 Month Average Volume | 13,621,573 |
Chart
About Abbott Laboratories (ABT)
Abbott Laboratories is a global healthcare company that specializes in the development of a wide range of medical devices, diagnostics, nutrition products, and pharmaceuticals. The company focuses on innovation to improve patient outcomes and enhance the quality of life for individuals worldwide. Abbott is known for its advancements in areas such as cardiovascular care, diabetes management, and nutrition science, providing essential tools and solutions that support healthcare professionals and patients in managing various health conditions. With a strong commitment to research and development, Abbott continually seeks to address unmet medical needs and contribute to the advancement of healthcare globally. Read More
News & Press Releases
Why is the Dow holding up while the Nasdaq sinks? Healthcare gains are offsetting the semiconductor carnage.
Via The Motley Fool · July 16, 2026
Unusual volume S&P500 stocks in Thursday's sessionchartmill.com
Via Chartmill · July 16, 2026
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Via Chartmill · July 16, 2026
Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters.
The company reaffirmed its full-year compara
Via MarketBeat · July 16, 2026
Abbott Laboratories NYSE:ABT Rises on In-Line Q2 and Raised Guidancechartmill.com
Via Chartmill · July 16, 2026
Dividend Powerhouse: Abbott Laboratories (NYSE:ABT) Passes the Test for Sustainable Incomechartmill.com
Via Chartmill · July 10, 2026
Abbott Laboratories (NYSE:ABT) Passes the Caviar Cruise Quality Screen with Strong Growth and Profitabilitychartmill.com
Via Chartmill · July 3, 2026
Abbott Laboratories (NYSE:ABT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts
Via Benzinga · July 16, 2026
Healthcare product and device company Abbott Laboratories (NYSE:ABT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 13% year on year to ...
Via StockStory · July 16, 2026
What's going on in today's pre-market session: S&P500 moverschartmill.com
Via Chartmill · July 16, 2026
Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.
Via The Motley Fool · July 8, 2026
Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.
Via MarketBeat · July 8, 2026
Don't sleep on these medical device leaders.
Via The Motley Fool · July 7, 2026
Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.
Via The Motley Fool · July 7, 2026
These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.
Via The Motley Fool · July 6, 2026
The Schwab U.S. Dividend Equity ETF is anything but boring.
Via The Motley Fool · July 3, 2026
Abbott's broad healthcare reach and Intuitive's robotic surgery focus present distinct financial strengths and risks for investors weighing portfolio strategy.
Via The Motley Fool · July 1, 2026
All three ETFs complement each other well in a portfolio.
Via The Motley Fool · June 30, 2026
AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.
Via The Motley Fool · June 29, 2026
Abbott Labs could rally in a downturn and has a long-term growth catalyst to boot.
Via The Motley Fool · June 28, 2026
These healthcare stocks may be the building blocks of a winning portfolio.
Via The Motley Fool · June 23, 2026
July earnings matter, but long-term growth matters more.
Via The Motley Fool · June 20, 2026
Now's the time to load up on these high-yielders.
Via The Motley Fool · June 15, 2026
Analysts remain relatively more upbeat, but this could prove fleeting.
Via The Motley Fool · June 13, 2026
Visa, Home Depot, and Abbott Laboratories are blue chip stocks that can provide your portfolio with a good mix of safety, stability, and dividend income over the long term.
Via The Motley Fool · June 9, 2026